

R Michael Tuttle

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/2346573/publications.pdf](https://exaly.com/author-pdf/2346573/publications.pdf)

Version: 2025-02-01

210

PR articles

29,545

PR citations

18011

59

PR h-index

4818

166

g-index

246

documents

36397

doc citations

13105

69

h-index

20519

citing authors

#	ARTICLE	IF	CITATIONS
1	High-Grade Follicular Cell-Derived Non-Anaplastic Thyroid Carcinoma: Correlating Extent of Invasion and Mutation Profile with Oncologic Outcome. <i>Thyroid</i> , 2025, 35, 153-165.	4.4	8
2	A Clinical Nomogram to Predict Survival Outcomes in Patients with Well-Differentiated Thyroid Cancer. <i>Thyroid</i> , 2025, 35, 397-405.	4.4	2
3	Partial Thyroidectomy With Incidental Metastatic Lymph Nodes. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2024, 150, 49.	3.0	9
4	Response to Letter to the Editor From Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2024, 109, e1684-e1684.	4.1	0
5	Redefining Actionable Disease in Well-differentiated Thyroid Cancer Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2024, 109, e2350-e2351.	4.1	0
6	Outcomes of Conversion Surgery for Patients With Low-Risk Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2024, 150, 1058.	3.0	8
7	Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions. <i>Annals of Surgical Oncology</i> , 2024, 31, 5525-5536.	2.3	6
8	Role of Locoregional Therapies in the Treatment of Thyroid Pathology: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2024, 35, 1752-1759.	1.1	1
9	Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 4761-4770.	2.3	7
10	Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 3135-3144.	4.1	7
11	Is There a Role for Levothyroxine Therapy in Euthyroid Patients on Active Surveillance for Papillary Microcarcinoma?. <i>Thyroid</i> , 2023, 33, 1137-1139.	4.4	2
12	Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?. <i>Surgery</i> , 2022, 171, 1341-1347.	1.8	11
13	Invasion of a Recurrent Laryngeal Nerve from Small Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance. <i>Thyroid</i> , 2022, 32, 164-169.	4.4	26
14	Enhancing Radioiodine Incorporation in BRAF -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. <i>Thyroid</i> , 2022, 32, 273-282.	4.4	47
15	Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes. <i>Thyroid</i> , 2022, 32, 245-254.	4.4	37
16	Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy. <i>Thyroid</i> , 2022, 32, 28-36.	4.4	35
17	Letter to the Editor From Boucai and Tuttle: "BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-Associated Mortality Risk in Papillary Thyroid Cancer" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2638-e2639.	4.1	1
18	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	2.0	100

#	ARTICLE	IF	CITATIONS
19	The solid variant of papillary thyroid carcinoma: a multi-institutional retrospective study. <i>Histopathology</i> , 2022, 81, 171-182.	3.6	17
20	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	4.4	27
21	Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 20-30.	1.9	7
22	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 62-72.	2.3	31
23	How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?. <i>Endocrine Practice</i> , 2021, 27, 607-613.	3.3	11
24	Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. <i>Clinical Endocrinology</i> , 2021, 94, 504-512.	2.3	9
25	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 6572-6579.	2.3	46
26	Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2021, 27, 383-389.	3.3	13
27	Abnormal growth rate of a benign cervical sympathetic chain schwannoma. <i>Otolaryngology Case Reports</i> , 2021, 19, 100295.	0.2	3
28	Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions.. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1798-1806.	1.7	7
29	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1009-1019.	4.4	84
30	Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021, 127, 4161-4170.	4.0	24
31	Nuances in the Surgical Management of Thyroid Cancer. <i>Indian Journal of Surgical Oncology</i> , 2021, 13, 1-6.	0.5	1
32	Papillary microcarcinoma—Management issues. <i>Indian Journal of Cancer</i> , 2021, 58, 155.	0.9	1
33	Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. <i>Surgery</i> , 2020, 167, 10-17.	1.8	65
34	Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. <i>NMR in Biomedicine</i> , 2020, 33, .	2.4	23
35	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e172-e180.	4.1	137
36	Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2020, 30, 688-695.	4.4	25

#	ARTICLE	IF	CITATIONS
37	ThyroidEx: Development and Preliminary Validation of a Thyroid Surgery Expectations Measure. Otolaryngology - Head and Neck Surgery, 2020, 165, 267-274.	2.3	4
38	Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 585.	3.0	11
39	Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Thyroid, 2020, 30, 1112-1119.	4.4	27
40	Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2020, 61, 375-396.	5.5	30
41	Active surveillance for patients with very low-risk thyroid cancer. Laryngoscope Investigative Otolaryngology, 2020, 5, 175-182.	1.6	38
42	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Modern Pathology, 2020, 33, 1690-1701.	4.8	60
43	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid, 2020, 30, 1505-1517.	4.4	252
44	Is a Prophylactic Central Compartment Neck Dissection Required in Papillary Thyroid Carcinoma Patients with Clinically Involved Lateral Compartment Lymph Nodes?. Annals of Surgical Oncology, 2020, 28, 512-518.	2.3	22
45	Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country. Endocrine, 2020, 72, 721-726.	2.5	4
46	How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid, 2019, 29, 1792-1803.	4.4	50
47	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4889-4899.	4.1	38
48	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. Annals of Surgical Oncology, 2019, 26, 4423-4429.	2.3	12
49	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocyctic features. Endocrine, 2019, 64, 97-108.	2.5	52
50	Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 99-108.	3.5	16
51	Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4087-4100.	4.1	145
52	Commentary "Incidence of total thyroidectomy and lobectomy". Surgery, 2019, 166, 48-49.	1.8	0
53	Enhanced interdisciplinary communication: development of an interactive thyroid nodule/cancer disease map. Laryngoscope, 2019, 129, 269-274.	1.4	1
54	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head and Neck, 2019, 41, 843-856.	2.0	12

#	ARTICLE	IF	CITATIONS
55	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019, 29, 7-26.	4.4	154
56	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	4.1	217
57	Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. <i>Surgery</i> , 2019, 165, 6-11.	1.8	54
58	Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. <i>Head and Neck</i> , 2018, 40, 663-675.	2.0	79
59	A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 77-85.	2.9	73
60	Controversial Issues in Thyroid Cancer Management. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1187-1194.	5.5	87
61	Treatment decision making in early-stage papillary thyroid cancer. <i>Psycho-Oncology</i> , 2018, 27, 61-68.	3.0	49
62	Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 55-63.	251.8	323
63	Risk Stratification in Differentiated Thyroid Cancer: Importance and Clinical Implications of Preoperative Risk Stratification. <i>VideoEndocrinology</i> , 2018, 5, .	0.1	1
64	Implementing Key Changes in The American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types. <i>Endocrine Practice</i> , 2018, 24, 833-840.	3.3	12
65	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	4.4	32
66	Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 1293-1300.	4.4	49
67	Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options. <i>Thyroid</i> , 2018, 28, 1325-1331.	4.4	53
68	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2017, 27, 512-517.	4.4	121
69	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 295-305.	5.1	51
70	The "broken chair" in patients with differentiated thyroid cancer. <i>Endocrine</i> , 2017, 57, 359-360.	2.5	1
71	Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. <i>Clinical Endocrinology</i> , 2017, 87, 566-571.	2.3	20
72	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017, 23, 5970-5980.	6.8	111

#	ARTICLE	IF	CITATIONS
73	Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-Risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 2299-2307.	1.8	8
74	Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2115-2116.	4.1	0
75	Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017, 123, 2955-2964.	4.0	82
76	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. <i>Thyroid</i> , 2017, 27, 632-640.	4.4	60
77	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1015.	3.0	433
78	Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 396-401.	4.4	38
79	Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 717-722.	5.5	97
80	The History of the Follicular Variant of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 15-22.	4.1	120
81	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <i>Endocrine</i> , 2017, 59, 143-150.	2.5	65
82	Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. <i>European Endocrinology</i> , 2017, 13, 26.	2.5	2
83	Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017, 26, 80-86.	0.7	11
84	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016, 38, 493-498.	2.0	96
85	Active Surveillance for Papillary Thyroid Microcarcinoma: New Challenges and Opportunities for The Health Care System. <i>Endocrine Practice</i> , 2016, 22, 602-611.	3.3	71
86	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1023.	14.4	1,332
87	Changing Trends in the Incidence of Thyroid Cancer in the United States. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 709.	3.0	178
88	Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States. <i>Thyroid</i> , 2016, 26, 989-990.	4.4	16
89	Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2692-2700.	4.1	213
90	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 933-942.	21.8	226

#	ARTICLE	IF	CITATIONS
91	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. <i>Thyroid</i> , 2016, 26, 1588-1597.	4.4	65
92	Multi-Institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 1708-1716.	2.8	56
93	Operative management of locally advanced, differentiated thyroid cancer. <i>Surgery</i> , 2016, 160, 738-746.	1.8	82
94	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016, 29, 985-995.	4.8	83
95	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 518-524.	4.4	51
96	An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 373-380.	4.4	199
97	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. <i>Thyroid</i> , 2016, 26, 219-226.	4.4	64
98	Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid. <i>Surgery</i> , 2016, 159, 1390-1395.	1.8	16
99	A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. <i>Thyroid</i> , 2016, 26, 144-149.	4.4	301
100	Management of advanced medullary thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 64-71.	21.8	116
101	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 1-133.	4.4	13,083
102	Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. <i>Journal of Cancer Survivorship</i> , 2016, 11, 302-308.	2.1	26
103	Serial Neck Ultrasound is More Likely to Identify False-Positive Abnormalities than Clinically Significant Disease in Low-Risk Papillary Thyroid Cancer Patients. <i>Endocrine Practice</i> , 2015, 21, 1372-1379.	3.3	50
104	Cost-effectiveness analysis of papillary thyroid cancer surveillance. <i>Cancer</i> , 2015, 121, 4132-4140.	4.0	56
105	RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system. <i>Laryngoscope</i> , 2015, 125, 2417-2424.	1.4	28
106	Practical Barriers to Implementation of Thyroid Cancer Guidelines in the Asia-Pacific Region. <i>Endocrine Practice</i> , 2015, 21, 1255-1268.	3.3	12
107	Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. <i>Thyroid</i> , 2015, 25, 865-866.	4.4	7
108	Management of Recurrent/Persistent Nodal Disease in Patients with Differentiated Thyroid Cancer: A Critical Review of the Risks and Benefits of Surgical Intervention Versus Active Surveillance. <i>Thyroid</i> , 2015, 25, 15-27.	4.4	130

#	ARTICLE	IF	CITATIONS
109	Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. <i>Thyroid</i> , 2015, 25, 1235-1242.	4.4	42
110	Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. <i>Cancer</i> , 2015, 121, 1793-1799.	4.0	79
111	Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. <i>Human Pathology</i> , 2015, 46, 657-664.	2.3	131
112	Using Diffusion-Weighted MRI to Predict Aggressive Histological Features in Papillary Thyroid Carcinoma: A Novel Tool for Pre-Operative Risk Stratification in Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 672-680.	4.4	36
113	Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3530-3536.	2.3	46
114	Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 503-508.	4.4	58
115	Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 662-667.	5.5	43
116	Frequent Screening With Serial Neck Ultrasound Is More Likely to Identify False-Positive Abnormalities Than Clinically Significant Disease in the Surveillance of Intermediate Risk Papillary Thyroid Cancer Patients Without Suspicious Findings on Follow-Up Ultrasound Evaluation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1561-1567.	4.1	44
117	Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. <i>Thyroid</i> , 2015, 25, 993-998.	4.4	52
118	Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?. <i>Thyroid</i> , 2015, 25, 1106-1114.	4.4	169
119	Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. <i>Human Pathology</i> , 2015, 46, 1789-1798.	2.3	82
120	Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 300-307.	4.4	146
121	Response to Initial Therapy Predicts Clinical Outcomes in Medullary Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 242-249.	4.4	91
122	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2015, 23, 410-415.	2.3	98
123	Restricting ultrasound thyroid fine needle aspiration biopsy by nodule size: which tumors are we missing? A population-based study. <i>Endocrine</i> , 2015, 51, 499-505.	2.5	7
124	Preoperative Neck Ultrasound in Clinical Node-Negative Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3686-3693.	4.1	16
125	Central Lymph Node Characteristics Predictive of Outcome in Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2014, 24, 1790-1795.	4.4	44
126	Multi-Organ Distant Metastases Confer Worse Disease-Specific Survival in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2014, 24, 1594-1599.	4.4	93

#	ARTICLE	IF	CITATIONS
127	The 2009 American Thyroid Association Guidelines Modestly Reduced Radioactive Iodine Use for Thyroid Cancers Less Than 1â€‰cm. <i>Thyroid</i> , 2014, 24, 1549-1550.	4.4	12
128	Prognostic Factors in Papillary Microcarcinoma with Emphasis on Histologic Subtyping: A Clinicopathologic Study of 148 Cases. <i>Thyroid</i> , 2014, 24, 245-253.	4.4	62
129	Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?. <i>Surgery</i> , 2014, 156, 1484-1490.	1.8	26
130	What Is the Gold Standard for Comprehensive Interinstitutional Communication of Perioperative Information for Thyroid Cancer Patients? A Comparison of Existing Electronic Health Records with the Current American Thyroid Association Recommendations. <i>Thyroid</i> , 2014, 24, 1466-1472.	4.4	16
131	Higher Administered Activities of Radioactive Iodine Are Associated with Less Structural Persistent Response in Older, but Not Younger, Papillary Thyroid Cancer Patients with Lateral Neck Lymph Node Metastases. <i>Thyroid</i> , 2014, 24, 1088-1095.	4.4	50
132	The impact of nodal status on outcome in older patients with papillary thyroid cancer. <i>Surgery</i> , 2014, 156, 137-146.	1.8	102
133	Update on Differentiated Thyroid Cancer Staging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 401-421.	3.5	178
134	Thyroid Carcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1671-1680.	12.6	156
135	Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2014, 22, 441-445.	2.3	1
136	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	16.6	859
137	Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems. <i>Thyroid</i> , 2013, 23, 1401-1407.	4.4	144
138	American Thyroid Association Statement on Outpatient Thyroidectomy. <i>Thyroid</i> , 2013, 23, 1193-1202.	4.4	262
139	Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging. <i>Oral Oncology</i> , 2013, 49, 695-701.	2.4	49
140	Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence. <i>Annals of Surgical Oncology</i> , 2013, 20, 2285-2289.	2.3	62
141	Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making. <i>Oral Oncology</i> , 2013, 49, 676-683.	2.4	40
142	A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients. <i>Thyroid</i> , 2013, 23, 436-442.	4.4	60
143	Recombinant Human Thyroid-Stimulating Hormone To Stimulate 131-I Uptake For Remnant Ablation And Adjuvant Therapy. <i>Endocrine Practice</i> , 2013, 19, 149-156.	3.3	10
144	Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. <i>Endocrine</i> , 2013, 47, 266-272.	2.5	27

#	ARTICLE	IF	CITATIONS
145	Oncologic Outcomes After Completion Thyroidectomy for Patients with Well-Differentiated Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 21, 1374-1378.	2.3	41
146	Recombinant Human Thyroid Stimulating Hormone- Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence. <i>Thyroid</i> , 2012, 22, 1007-1015.	4.4	76
147	Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic BRAF Mutation Status, the Number of Nodal Metastases, and Extra-Nodal Extension. <i>Thyroid</i> , 2012, 22, 575-584.	4.4	116
148	Even Without Additional Therapy, Serum Thyroglobulin Concentrations Often Decline for Years After Total Thyroidectomy and Radioactive Remnant Ablation in Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 778-783.	4.4	87
149	The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension. <i>Thyroid</i> , 2012, 22, 1144-1152.	4.4	749
150	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	4.4	776
151	Changing trends in well differentiated thyroid carcinoma over eight decades. <i>International Journal of Surgery</i> , 2012, 10, 618-623.	5.4	37
152	American Thyroid Association Statement on the Essential Elements of Interdisciplinary Communication of Perioperative Information for Patients Undergoing Thyroid Cancer Surgery. <i>Thyroid</i> , 2012, 22, 395-399.	4.4	71
153	Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell-Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy Whole-Body Scans. <i>Thyroid</i> , 2012, 22, 877-883.	4.4	59
154	American Thyroid Association Design and Feasibility of a Prospective Randomized Controlled Trial of Prophylactic Central Lymph Node Dissection for Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2012, 22, 237-244.	4.4	209
155	Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing-related increases in body mass in thyroid cancer survivors. <i>Clinical Endocrinology</i> , 2012, 76, 582-585.	2.3	30
156	Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. <i>Clinical Endocrinology</i> , 2012, 77, 132-138.	2.3	247
157	Ultrasonographically Detected Small Thyroid Bed Nodules Identified After Total Thyroidectomy for Differentiated Thyroid Cancer Seldom Show Clinically Significant Structural Progression. <i>Thyroid</i> , 2011, 21, 845-853.	4.4	130
158	Similarities and Differences in Follicular Cell-Derived Thyroid Cancer Management Guidelines Used in Europe and the United States. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 89-95.	4.9	11
159	A Risk-Adapted Approach to the Use of Radioactive Iodine and External Beam Radiation in the Treatment of Well-Differentiated Thyroid Cancer. <i>Cancer Control</i> , 2011, 18, 89-95.	2.2	37
160	Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. <i>Clinical Endocrinology</i> , 2011, 75, 112-119.	2.3	180
161	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. <i>Cancer</i> , 2011, 117, 4439-4446.	4.0	287
162	Disease-Related Death in Patients Who Were Considered Free of Macroscopic Disease After Initial Treatment of Well-Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2011, 21, 501-504.	4.4	23

#	ARTICLE	IF	CITATIONS
163	In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response. <i>Thyroid</i> , 2011, 21, 1317-1322.	4.4	130
164	Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. <i>Indian Journal of Surgical Oncology</i> , 2011, 3, 182-189.	0.5	7
165	Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function. <i>Thyroid</i> , 2010, 20, 257-263.	4.4	61
166	Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System. <i>Thyroid</i> , 2010, 20, 1341-1349.	4.4	863
167	The Effect of Posttherapy ¹³¹ I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1361-1367.	5.5	110
168	Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td	2.3	80
169	Mild Decreases in White Blood Cell and Platelet Counts Are Present One Year After Radioactive Iodine Remnant Ablation. <i>Thyroid</i> , 2009, 19, 1035-1041.	4.4	45
170	Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2009, 19, 1167-1214.	4.4	6,330
171	Encapsulated Papillary Thyroid Carcinoma: A Clinico-Pathologic Study of 106 Cases with Emphasis on Its Morphologic Subtypes (Histologic Growth Pattern). <i>Thyroid</i> , 2009, 19, 119-127.	4.4	134
172	Medical management of thyroid cancer: a risk adapted approach. <i>Journal of Surgical Oncology</i> , 2008, 97, 712-716.	1.5	58
173	Follow up Approaches in Thyroid Cancer: A Risk Adapted Paradigm. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 419-435.	3.5	107
174	ret/PTC Activation Is Not Associated with Individual Radiation Dose Estimates in a Pilot Study of Neoplastic Thyroid Nodules Arising in Russian Children and Adults Exposed to Chernobyl Fallout. <i>Thyroid</i> , 2008, 18, 839-846.	4.4	24
175	Recombinant Human TSH Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal. <i>Journal of Nuclear Medicine</i> , 2008, 49, 764-770.	5.5	146
176	Risk-Adapted Management of Thyroid Cancer. <i>Endocrine Practice</i> , 2008, 14, 764-774.	3.3	83
177	Impact of Pregnancy on Serum Thyroglobulin and Detection of Recurrent Disease Shortly After Delivery in Thyroid Cancer Survivors. <i>Thyroid</i> , 2007, 17, 543-547.	4.4	56
178	Papillary Thyroid Cancer: Monitoring and Therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 753-778.	3.5	74
179	Microarray Comparative Genomic Hybridization Reveals Genome-Wide Patterns of DNA Gains and Losses in Post-Chernobyl Thyroid Cancer. <i>Radiation Research</i> , 2006, 166, 519-531.	2.1	24
180	Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce. <i>Thyroid</i> , 2006, 16, 109-142.	4.4	1,898

#	ARTICLE	IF	CITATIONS
181	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. <i>Cancer</i> , 2006, 106, 1286-1295.	4.0	305
182	Follicular variant of papillary thyroid carcinoma. <i>Cancer</i> , 2006, 107, 1255-1264.	4.0	382
183	Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 498-505.	4.1	550
184	BRAF Mutations are Uncommon in Papillary Thyroid Cancer of Young Patients. <i>Thyroid</i> , 2005, 15, 320-325.	4.4	114
185	Thyroid Cancers Express CD-40 and CD-40 Ligand: Cancers That Express CD-40 Ligand May Have a Greater Risk of Recurrence in Young Patients. <i>Thyroid</i> , 2005, 15, 105-113.	4.4	9
186	Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 57, 7-14.	2.1	55
187	Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2281-2289.	4.1	44
188	Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6010-6016.	4.1	75
189	Differentiated Thyroid Carcinomas from Children and Adolescents Express IGF-I and the IGF-I Receptor (IGF-I-R). Cancers with the Most Intense IGF-I-R Expression May Be More Aggressive. <i>Pediatric Research</i> , 2004, 55, 709-715.	2.3	33
190	Cytoplasmic Localization of the Paired Box Gene, Pax-8, is Found in Pediatric Thyroid Cancer and May Be Associated With a Greater Risk of Recurrence. <i>Thyroid</i> , 2004, 14, 1037-1046.	4.4	20
191	Papillary Thyroid Carcinomas from Young Adults and Children Contain a Mixture of Lymphocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4418-4425.	4.1	67
192	Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 53, 409-414.	2.1	6
193	Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude Mice. <i>Thyroid</i> , 2002, 12, 953-961.	4.4	65
194	Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents. <i>Pediatric Research</i> , 2002, 52, 737-744.	2.3	57
195	Is the Serum Thyroglobulin Response to Recombinant Human Thyrotropin Sufficient, by Itself, to Monitor for Residual Thyroid Carcinoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3242-3247.	4.1	136
196	Intense Expression of the B7-2 Antigen Presentation Coactivator Is an Unfavorable Prognostic Indicator for Differentiated Thyroid Carcinoma of Children and Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4391-4397.	4.1	20
197	Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents. <i>Pediatric Research</i> , 2002, 52, 737-744.	2.3	7
198	Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid Cancer. <i>Modern Pathology</i> , 2001, 14, 289-296.	4.8	95

#	ARTICLE	IF	CITATIONS
199	Infiltration of Differentiated Thyroid Carcinoma by Proliferating Lymphocytes Is Associated with Improved Disease-Free Survival for Children and Young Adults ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1346-1354.	4.1	78
200	Resistance of [18F]-Fluorodeoxyglucose-Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive Iodine. <i>Thyroid</i> , 2001, 11, 1169-1175.	4.4	178
201	The Chernobyl accident and its consequences: Update at the millennium. <i>Seminars in Nuclear Medicine</i> , 2000, 30, 133-140.	4.9	137
202	Theret/PTC Mutations Are Common in Sporadic Papillary Thyroid Carcinoma of Children and Young Adults ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1170-1175.	4.1	203
203	Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 0, , .	4.4	7
204	RAS -Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance. <i>Thyroid</i> , 0, , .	4.4	6
205	Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	4.1	1
206	The prognostic impact of blood vessel invasion in infiltrative papillary thyroid carcinoma: a retrospective caseâ€“control study. <i>Histopathology</i> , 0, 88, 673-682.	3.6	0
207	Scholarly Dialogue on Risk to the Recurrent Laryngeal Nerve with Thermal Ablation Procedures: A Reflection on Empirical Practices. <i>Thyroid</i> , 0, 35, 1221-1229.	4.4	0
208	Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance. <i>Journal of the Endocrine Society</i> , 0, 10, .	0.3	0
209	Clinical and genomic characterization of brain metastasis in thyroid cancer. <i>Journal of Neuro-Oncology</i> , 0, 176, .	2.5	0
210	Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 0, , .	3.0	0